MAPK14 and Alzheimer disease: The NMDA receptor antagonist memantine is now a widely used treatment for Alzheimer’s disease [86], and p38 MAP kinase inhibitors have been developed for therapy of inflammatory diseases [87] and CNS disorders, including Alzheimer’s disease [88–90].